BriaCell Therapeutics (NASDAQ:BCTX – Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.14), Zacks reports.
BriaCell Therapeutics Stock Performance
Shares of BCTX stock opened at $0.61 on Tuesday. BriaCell Therapeutics has a fifty-two week low of $0.46 and a fifty-two week high of $5.97. The firm has a market capitalization of $22.00 million, a PE ratio of -0.52 and a beta of 1.46. The stock’s 50-day simple moving average is $0.83 and its 200-day simple moving average is $0.87.
Analyst Ratings Changes
Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of BriaCell Therapeutics in a research note on Thursday, December 12th.
BriaCell Therapeutics Company Profile
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.
Featured Stories
- Five stocks we like better than BriaCell Therapeutics
- 5 Top Rated Dividend Stocks to Consider
- Why Costco’s Rally May Continue Into 2025
- What Are Dividends? Buy the Best Dividend Stocks
- 3 Growth Stocks to Grab for Less Than $100
- What is the Euro STOXX 50 Index?
- Semtech Stock Climbs as AI Boom Drives Turnaround Success
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
